Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.
Rolle CP, Berhe M, Singh T, Ortiz R, Wurapa A, Ramgopal M, Jayaweera DT, Leone PA, Matthews JE, Cupo M, Underwood MR, Angelis K, Wynne BR, Merrill D, Nguyen C, van Wyk J, Zolopa AR.
Rolle CP, et al. Among authors: matthews je.
Open Forum Infect Dis. 2023 Mar 1;10(3):ofad101. doi: 10.1093/ofid/ofad101. eCollection 2023 Mar.
Open Forum Infect Dis. 2023.
PMID: 36968959
Free PMC article.